Prolonged systemic inflammation worsens impairments to astrocyte Ca^{2+} and functional hyperemia in Alzheimer's disease

Chang Liu[1], Kimia Sakha[1], Jaime Anton[1], Alfredo Cardenas-Rivera[1], Mohammad A. Yaseen[1]

HIGHLIGHTS

- Astrocytes in AD mice exhibit increased spontaneous Ca^{2+} signaling but cannot sustain stimulus-evoked Ca^{2+} release.
- Reduced astrocyte Ca^{2+} release during 30s functional brain activation correlates with impaired neurovascular coupling in both penetrating arterioles and capillaries of AD mice
- A secondary, 14-day systemic inflammatory challenge further suppressed functional hyperemia of 30 s stimulus–evoked astrocytic Ca^{2+} release in AD mice.
- A secondary inflammatory insult lasting 14 days reduced amyloid deposition in the AD brain.

SUMMARY

Chronic neuroinflammation in Alzheimer's disease (AD) activates astrocytes—key regulators of both brain immunity and neurovascular coupling. The primed immune environment in AD brain also renders it highly susceptible to secondary systemic inflammatory challenges. Inflammatory activation drives phenotypic shifts in astrocytes that may compromise their ability to regulate cerebral blood flow. The capacity for inflammation-activated astrocytes to retain this regulatory function, however, remains unknown. To investigate astrocyte regulation of cerebral blood flow in AD brain and under systemic inflammation, we investigated astrocytic Ca^{2+} dynamics and functional hyperemia at rest and during brief and prolonged sensory stimulation in 12-month-old female APP/PS1dE9 mice. We further examined how a secondary systemic inflammatory challenge induced by low-dose, repeated injection of LPS modulates astrocytic signaling and neurovascular function. AD mice exhibited elevated spontaneous but diminished stimulation-evoked astrocytic Ca^{2+} activity, accompanied by impaired sustained functional hyperemia, particularly within the capillary network. LPS-induced systemic inflammation further suppressed both spontaneous and evoked astrocytic Ca^{2+} responses and attenuated functional hyperemia. Together, these findings reveal that inflammation disrupts astrocyte-dependent regulation of sustained neurovascular responses in the AD brain.

Keywords: Neuroinflammation, astrocyte Ca^{2+}, neurovascular coupling, Alzheimer's disease, two-photon microscopy, lipopolysaccharide

Author affiliations:
1 Department of Bioengineering, Northeastern University, Boston, MA 02115, USA

Correspond to:
    Mohammad Abbas Yaseen
    Northeastern University BIOE,
    360 Huntington Ave, ISEC 206
    Boston, MA 02115
    m.yaseen@northeastern.edu

1. INTRODUCTION

Vascular dysfunction and neuroinflammation are two major pathological features of preclinical Alzheimer's disease (AD) and other diseases of the central nervous system (CNS) [1–4]. These notable AD hallmarks are coupled through their shared cellular components, with astrocytes performing especially critical roles in regulating both microvascular blood flow and brain immunity [5,6]. Astrocyte excitability is mediated primarily by Ca^{2+} signaling and is crucial for numerous immune, synaptic, metabolic, and hemodynamic signaling pathways of the "neuro-glio-vascular unit" (NGVU) [7–9]. In response to stress, injury, or disease-related alterations, astrocytes undergo phenotypic and morphological changes to a reactive state. Reactive astrocytes demonstrate altered excitability, dysregulated Ca^{2+} signaling, altered gene expression, metabolic shifts, and active release pro- or anti-inflammatory cytokines, and they contribute notably to AD progression and other CNS disorders [7,10,11]. In AD and other disorders, reactive astrocytes reportedly facilitate amyloid beta (Aβ) pathology and neural network dysfunction [7,8]. The impact of inflammatory astrocyte phenotype alterations on their contributions to cerebral blood flow regulation is presently unclear.

Neuroinflammation reportedly potentiates Aβ accumulation, cerebrovascular pathology, mitochondrial dysfunction, reactive oxygen species generation, and synaptic loss. Thus, it is increasingly recognized as a driving force and critical accelerator for the aggressive cycle of pathological deteriorations in preclinical AD and other neurodegenerative disorders [14,15]. Many investigators assert a nuanced influence of neuroinflammation, citing evidence of both harmful and beneficial effects of an inflammatory stimulus during disease progression [16,17]. Several studies also highlight the importance of the brain's initial inflammatory state on subsequent outcomes to a secondary inflammatory threat. At early stages of AD or other neurodegenerative diseases, acute periods of illness or systemic inflammation can catalyze chronic neuroinflammation and exacerbate neurotoxicity and functional decline [18–21]. Collectively, these views motivate investigations to explore the effects of enhancing or repressing a pro-inflammatory response on chronic cerebral pathologies [22].

Previous studies also show that acute systemic inflammation disrupts cerebral hemodynamics in healthy rodent brains and human patients with small vessel disease and traumatic brain injury [23–25]. To precisely elucidate the intricate relationship between neuroinflammation and vascular dysfunction in preclinical AD, a detailed understanding of neuroinflammation's impact on astrocyte Ca^{2+}-mediated microvascular hemodynamics is essential. In this study, we investigated the effects of amyloid-induced inflammation coupled with a prolonged systemic inflammatory threat on astrocyte Ca^{2+} signaling and cerebral blood flow. 12-13 month-old female APPswe/PS1dE9 mice and their wildtype littermates (n=8 each) were exposed to a 14-day period of systemic inflammation induced by intraperitoneal injection of the bacteria-derived endotoxin

lipopolysaccharide injection (LPS) [26]. Using intravital two-photon microscopy, we longitudinally measured Ca^{2+} release from astrocytes and microvascular hemodynamics in penetrating arterioles and capillary branches under resting state conditions and during functional brain activation in the awake mouse brain. Our observations demonstrate that Aβ-induced inflammatory disruptions notably alter astrocyte Ca^{2+} and sensory-evoked microvascular responses. A prolonged period of LPS-induced inflammation further exacerbated astrocyte Ca^{2+} signaling and the hyperemic response to longer, 30 second functional stimulation. Immunofluorescence imaging showed reduced levels of cortical and hippocampal Aβ after 14-days of induced inflammation. The results delineate the interdependent relationships between astrocyte Ca^{2+} signaling, neuroimmune and neurovascular dynamics, and Aβ pathology during preclinical AD's multifactorial progression.

2. RESULTS

Among its many functions, astrocyte Ca^{2+} is an important modulator of basal blood flow and functional hyperemia in the brain [6,27]. To determine whether Aβ-induced inflammatory astrogliosis alters astrocyte Ca^{2+}-mediated contributions to cerebral blood flow regulation, we measured astrocyte Ca^{2+} dynamics and microvascular dilation under resting-state conditions and during sensory-evoked functional hyperemia in the awake mouse brain at age 12-13 months in APPswe/PS1dE9 and wildtype mice. We then explored if a 14-day LPS-induced neuroinflammation challenge alters astrocyte calcium signaling and its contributions to neurovascular coupling. Systemic injection of the bacteria-derived endotoxin lipopolysaccharide (LPS) has been extensively used as an effective model to study neuroinflammation in neurodegenerative disease [26].

Recent studies demonstrate that astrocyte Ca^{2+} contributes significantly to sustaining functional hyperemia in response to prolonged, but not brief, periods of cortical stimulation [28]. Motivated by these findings, we used two-photon imaging to measure brain hemodynamics and astrocyte Ca^{2+} release in response to both brief (3s) and sustained (30s) whisker stimulation.

Intravital two-photon microscopy measurements were performed in cortical layers I and IV of awake mice. Data from both layers were combined.

2.1 Pre-inflammation: Hyperactive astrocytes and reduced stimulus-evoked astrocyte Ca^{2+} in AD mice

We first evaluated resting-state spontaneous cortical astrocyte Ca^{2+} by imaging GCaMP6f-labelled astrocytes

in awake mice. Raster scanning was performed in ~88 μm^2 cortical regions surrounding penetrating arterioles

for 10 min at ~ 4.4 Hz (Fig. 1A). Dynamic Ca^{2+} transients were quantified and analyzed from the soma,

processes, and endfoot compartments of astrocytes. In AD mice, we observed ~15 – 40% higher frequencies

of Ca^{2+} spikes compared to age-matched wildtype littermates, with significantly higher Ca^{2+} frequency in the

soma and process compartments (Fig. 1B-C, left, p-val = 0.03 soma, p-val = 0.048 processes). No differences

in the Ca^{2+} amplitudes were observed between AD and WT mice. Compared to WT littermates, the mean

duration of the astrocytic Ca^{2+} spikes in AD mice was significantly lower (26%, p-val < 1e-4) in astrocyte

processes. Shorter Ca^{2+} durations were also observed in the soma and endfoot compartments in AD mice;

however, the differences did not reach statistical significance (Fig. 1C).

Next, we investigated whether amyloid pathology impacts functional hyperemia. We first applied optical

intrinsic signal imaging (OISI) during a 3 s whisker stimulus to locate the activation center (Fig. 1D). We

measured astrocyte Ca^{2+} dynamics and diameter of penetrating arterioles while stimulating the mouse barrel

cortex via pneumatic whisker deflection. Our OISI measurement revealed slight, but not significant,

differences in peak cerebral blood volume response (< -1%) in AD mice relative to WT (Fig. 1D). The

activated region was then imaged via TPM using both raster scanning (4.4 Hz, Fig 1E) and rapid line

scanning (~360 – 100 Hz, downsampled to 20 Hz during data processing).

In response to a short ~3s functional stimulus, AD and WT mice demonstrated different responses for arterial

dilation and Ca^{2+} signaling within astrocyte compartments. The area under the curve (AUC) for arterial

dilation response was significantly lower in AD mice (40% difference, p = 0.029), while arterial peak

dilation, rise times, and latency were similar between cohorts (Fig.1F and supplementary Fig. 1). Astrocyte

Ca^{2+} kinetics varied in different astrocytic microdomains, as reported previously [29]. Peak amplitudes of

stimulus-induced Ca^{2+} release in AD mice appeared higher in all astrocyte compartments compared to WT

mice; however, the differences did not achieve statistical significance (Fig. 1 G-I, soma p = 0.23, endfeet p =

0.21, processes p= 0.054). AD mice demonstrated significantly shorter Ca^{2+} responses in astrocytic endfeet

(supplementary Fig. 1, p = 7e-4). In both cohorts, we consistently observed that the short 3s whisker stimulus

evoked slower astrocyte Ca^{2+} responses relative to the arteriole response. Arterioles dilated to their maximum

approximately 2.1 seconds after the stimulus onset, while all astrocyte Ca^{2+} release required 4 - 4.5 s to reach

their peak values (~ 1-1.5 s after stimulus cessation). Our results indicate that astrocytes in the AD mice brain

respond slightly faster and more pronouncedly than WT mice to brief sensory stimulation.

A longer 30s whisker stimulus yielded more striking differences between AD and WT mice, particularly in

astrocyte Ca^{2+} dynamics. Response profiles exhibited biphasic features for both arterial dilation and astrocyte

Ca^{2+} release - including a rapid rising phase followed by a prolonged plateau phase. Consequently, we

analyzed dilation and Ca^{2+} release both over the full stimulus duration (all 30 seconds) as well as the late

phase (the final 2 seconds). Again, AD and WT mice experienced comparable peak diameter in arterioles

within the first 3 seconds of stimulation. Following peak dilation, arterioles constricted slightly and plateaued

to a smaller diameter (Fig. 1J). For both phases, we observed no significant differences in arterial dilation rise

times, maximal diameter, or AUC between AD and WT mice. However, following stimulus cessation, we

observed significantly faster constriction to baseline diameter in AD mice (Supplementary Fig. 1E, Δt =

5.04s, p = 0.03). Astrocyte Ca^{2+} responses differed more substantially between cohorts for the 30 s stimulus

(Fig. 1 K-M & Supplementary Fig.1 F-H). In astrocyte soma and endfeet, both AD and WT mice achieved

similar peak values of Ca^{2+} release, but AD mice achieved their peak significantly earlier. In WT mice,

astrocytes persistently released Ca^{2+} from all compartments until the stimulus cessation, while Ca^{2+} release in

AD astrocyte peaked rapidly during the first ~5s of stimulation and diminished markedly thereafter. Within

processes, AD mice demonstrated significant lower peak Ca^{2+} release (Fig. 1M & Supplementary Fig. 1H, p <

1e-4). For all astrocyte compartments, Ca^{2+} release was significantly lower in AD mice during the final 2s of

the stimulus (Fig.1 K-M, soma p = 1e-4, endfeet p = 7e-4, processes p < 1e-4). Our observations indicate a

compartmentalized influence of AD pathology to astrocyte Ca^{2+}. In all microdomains, AD mice could not

sustain astrocytic Ca^{2+} release in response to longer 30 s sensory stimulation, indicating reduced Ca^{2+} storage.

The influence of astrocytes on microvascular blood flow reportedly extends beyond penetrating arterioles to

laterally-oriented pre-capillary arterioles and capillaries [29,30]. In this dense network of small, more

prevalent microvessels, even modest alterations to vessel diameter can substantially impact vascular

resistance and total blood flow [31].   To examine how amyloid pathology and associated hyperactive

astrocytes affect hemodynamics in these vessels, we performed rapid two-photon line scan measurements to

measure capillary diameter and red blood cell speed. Vessel dilation and RBC speed in laterally-oriented

arteriole branches and capillary branches extending from the downward penetrating arteriole (1st order to 4th

order) were measured and downsampled to a rate of 20Hz. The vessels were further grouped as precapillary

arteriole (1st to 2nd order) and high-order capillaries (≥3rd order) (Supplementary Fig. 2A). Baseline vessel

diameters were computed as the mean diameter between 1.5 to 4.5s of the 5s baseline period (Supplementary

Fig. 2B). In AD mice, we observed significantly faster RBC speed in high-order capillaries compared to WT

mice, suggesting higher blood flow and lower vascular resistance (Supplementary Fig. 2C). For the short 3s

stimulus duration, we observed no differences in relative peak dilation for pre-capillary arterioles or

capillaries (Supplementary Fig. 2D-F). For a longer 30 second stimulus, however, responses from higher-

order capillaries in AD mice had significantly lower diameters during the last 2 seconds and AUC

(Supplementary Fig. 2 H).

Fig. 1. Spontaneous astrocyte Ca^{2+} and sustained sensory stimulation in AD and WT mice barrel cortex. (A)
2D, raster scan image (average intensity projection of a 10-minute time series) showing vasculature labelled with
Texas-Red and astrocyte microdomains expressing GCaMP6f. Annotated regions are soma (red), endfeet (blue), and
process (yellow). **(B)** Representative measurements of spontaneous Ca^{2+} release in cortical astrocytes cell
compartments recorded for 10 mins. **(C)** Amplitude, Frequency and Duration of Ca^{2+} spikes at different astrocyte
ROIs. For WT mice, 25 somas and 156 processes were measured from 8 mice, and 14 endfoot were measured from
7 mice. For AD mice, 30 somas, 101 processes, and 12 endfoot were measured from 8 mice. **(D)** OISI measurement
of cerebral hemodynamics in response to 3s whisker stimulation in left barrel cortex in WT and AD mice. **(E)**
Representative two-photon raster scan images of diving arteriole dilation and astrocyte Ca^{2+} release during a 30s

whisker stimulation trial. **(F-I):** Trial-averaged profiles of arteriole dilation and astrocyte Ca^{2+} release in response to
3s whisker stimulation and quantification of the peak response. **(J-M):** Trial-averaged profiles of arteriole dilation
and astrocyte Ca^{2+} release in response to 30s whisker stimulation and the quantification of the peak response.
Difference between WT and AD were tested using rank-sum test.

2.2 LPS-induced inflammation reduces spontaneous astrocyte Ca^{2+} and impairs neurovascular coupling

To evaluate how prolonged systemic inflammation alters astrocyte's Ca^{2+} signaling and its contributions to

CBF regulation, animals underwent a 14-day LPS-induced inflammation challenge. We used 2-photon

imaging to measure astrocyte Ca^{2+} dynamics and microvascular dilation under resting-state conditions and

during functional hyperemia in awake AD and WT mice. The same imaging fields of view were imaged on

days 0, 7, and 14 of LPS administration.

Fig. 2A displays example measurements of resting-state, spontaneous Ca^{2+} release from astrocytic

compartments over the course of the 14-day inflammatory threat. Once again, raster scanning was performed

in ~88 μm^2 cortical regions surrounding penetrating arterioles for 10 min at ~ 4.4 Hz. We observed no

discernible differences in astrocyte morphology from days 0 – 14. Dynamic Ca^{2+} transients were quantified

and analyzed from the soma, processes, and endfeet compartments of astrocytes (Fig. 2 B & C). During the

14-day period, we observed variations in spontaneous Ca^{2+} fluctuations in astrocytes in both cohorts, with

some cell compartments demonstrating no Ca^{2+} transients over the 10-minute measurement. Fig. 2D

illustrates how the proportion of these 'silent,' quiescent cell compartments changed during the inflammatory

period. Among the cells that remained active in both AD and WT cohorts, the frequency of spontaneous Ca^{2+}

spikes progressively lowered during the 14-day period within astrocyte soma and process compartments (Fig.

2E&G). No substantial changes were observed in endfeet Ca^{2+} (Fig. 2F).

Fig. 2. LPS induced inflammation decreased spontaneous Ca^{2+} release in astrocytes in AD mice cortex. (A) Raster scan image of cortical vasculature and astrocytes at different days during 14-days of LPS-induced systemic inflammation (average intensity projections from 10-minute time series). **(B)** Spontaneous Ca^{2+} release form astrocyte compartments in WT and AD mice cortex measured on pre-LPS injection (day 0), after 7 and 14 days of LPS injection (day 7 and day14). **(D)** Variations in spontaneous Ca^{2+} activity from astrocyte compartments during the 14-day period. **(E-G)** Quantification of astrocyte Ca2+ spikes under the impact of LPS induced inflammation. Linear mixed effect model was used to test the effect of LPS injection. WT mice day0 measurement: 25 somas, 156 processes and 14 endfoot measured from 8, 8, and 7 mice, respectively. WT mice day7 measurement: 23 somas, 111 processes and 17 endfoot measured from 8, 8, and 8 mice. WT mice day14 measurement: 12 somas, 46 processes and 8 endfoot measured from 4, 6 and 6 mice. AD mice day0 measurement: 30 somas, 101 processes and 12 endfoot measured from 8, 8, and 8 mice. AD mice day7 measurement: 22 somas, 103 processes and 11 endfoot measured from 7, 8 and 7 mice. AD mice day 14 measurement: 16 somas, 68 processes and 8 endfoot measured from 5, 7 and 5 mice.

To determine whether prolonged systemic inflammation impacts astrocytic contributions to functional hyperemia, we again examined dilation of penetrating arterioles and astrocyte Ca^{2+} release in response to brief (3s) and sustained (30 s) pneumatic whisker stimulation. For short 3s whisker stimulation, arteriole dilation responses did not change appreciably during the 14-day period for both AD and WT mice (Fig. 3A), while astrocyte Ca^{2+} responses varied significantly. In the astrocyte soma of WT mice, Ca^{2+} release parameters showed reductions in peak response and AUC between days 0 and 7 (Fig. 3B, p-val = 0.036 and p-val = 0.047, respectively). For both AD and WT mice, systemic inflammation substantially altered Ca^{2+} release in astrocyte processes, provoking significant reductions in peak Ca^{2+} release, AUC, and rise time (Fig. 3D).

183   Interestingly, the inflammatory threat induced opposing effects in AD and WT mice within astrocyte endfeet.

184   In WT mice, we observed significant increases in peak Ca^{2+} of endfeet and shorter response duration.

185   Conversely, in AD mice, endfeet showed reduced peak Ca^{2+} and significantly longer rise times, but longer

186   duration (Fig. 3C & Supplementary Fig. 3).

Fig. 3. Effect of LPS induced inflammation on penetrating arterial dilation and astrocyte Ca^{2+} release in response to brief whisker 3s stimulation. (**A**) Trial-averaged profiles and calculated features of stimulus-induced penetrating arteriole dilation in WT and AD mice on day 0 (WT: N=22 arterioles, n=7 mice; AD: N=19 arterioles, n=8 mice), day7 (WT: N=22 arterioles, n=8 mice; AD: N=17 arterioles, n=8 mice), and day14 of LPS injection (WT: N=15 arterioles, n=5 mice. AD: N=13 arterioles, n=6 mice). (**B-D**) Trial-averaged profiles and calculated features of stimulus-induced, compartment-specific astrocyte Ca^{2+} release in WT and AD mice on day 0 (WT: N=23 soma from 8 mice, N=20 endfoot from n=7 mice, N=88 processes from n= 8 mice. AD: N=21 soma from 7 mice, N=18 endfoot from 8 mice, N=77 processes from 7 mice) , day7 (WT: N=29 soma from 7 mice, N=15 endfoot from n=6 mice, N=86 processes from 8 mice. AD: N=28 soma from 7 mice, N=16 endfoot from 8 mice, N=86 processes from 8 mice) and day14 of LPS injection (WT: N=15 soma from 5 mice, N=15 endfoot from n=5 mice, N=25 processes from 5 mice. AD: N=19 soma from 5 mice, N=10 endfoot from 6 mice, N=62 processes from 6 mice).

For longer 30 second whisker stimulation, the 14-day inflammatory threat provoked more pronounced

alterations to WT mice than AD mice. Again, more significant inflammation-induced alterations were

observed in astrocytes than arterioles. In both AD and WT mice, arteriole dilation was reduced during the

later plateau phase at days 7 and 14 (Fig. 4A) and AD mice showed significantly slower restoration to

baseline diameter (supplementary Fig. 4A). In WT mice, peak Ca^{2+} release and rise times during the entire 30

s stimulation all significantly decreased in soma and processes over the 14-day inflammatory period, and peak

latency was also significantly decreased in processes. AUC significantly lowered within all compartments

(Fig. 4 B-D). Maximum Ca^{2+} release during the late phase of stimulation were also significantly reduced in all

compartments (Fig. 4 B-D). In AD mice, the inflammatory threat provoked significant reductions in peak

Ca^{2+} release from all astrocyte compartments. The AUC for responses in astrocyte endfeet also decreased

significantly during the inflammation period in AD mice, while astrocyte processes showed significant

reductions in AUC, peak latency, duration, and the average Ca^{2+} release during the later plateau phase (Fig. 4

D & supplementary Fig. 4D). Overall, our observations at the late phase of stimulation show reduced endfeet

Ca^{2+} release that correlate well with mildly reduced penetrating arteriole dilation and slower post-stimulus

constriction. The results align well with prior studies demonstrating that astrocyte Ca^{2+} does not initiate

arteriole dilation but is required to sustain dilation and mediate recovery from prolonged functional

stimulation [28].

We then examined how inflammation impacts stimulus-evoked dilation of laterally-oriented pre-capillary

arterioles and capillaries. Using rapid line scan measurements, we measured kinetic profiles of stimulus

induced vessel dilation and RBC velocity in lateral arterioles and capillary branches. The line scan

measurements from enveloping astrocyte endfeet and neighboring processes further indicate that systemic

inflammation impairs their stimulus-evoked Ca^{2+} release; however, we observed no significant LPS-induced

alterations in vessel dilation or RBC velocity from capillaries or pre-capillary arterioles (supplementary

figures 5-7).

Fig. 4. Effect of LPS induced inflammation on penetrating arteriole dilation and astrocyte Ca^{2+} release in response to 30 second whisker stimulation. (**A**) Trial-averaged profiles and calculated features of stimulus-induced penetrating arteriole dilation in WT and AD mice on day 0 (WT: N= 18 arterioles, n=7 mice. AD: N=18 arterioles, n=8 mice), day7 (WT: N=18 arterioles, n=8 mice. AD: N=19 arterioles, n=8 mice), and day14 of LPS injection (WT: N= 9 arterioles, n=5 mice, AD: N=14 arterioles, n=6 mice). (**B-D**) Trial-averaged profiles and calculated features of stimulus-induced, compartment-specific astrocyte Ca^{2+} release in WT and AD mice on day 0 (WT: N=26 soma from 8 mice, N=19 endfoot from n= 7 mice, N= 114 processes, from n=8 mice. AD: N=24 soma from 7 mice, N=18 endfoot from 8 mice, N=94 processes from 7 mice), day7 (WT: N=28 soma from 8 mice, N=18 endfoot from n=8 mice, N=98 processes from 8 mice. AD: N=32 soma from 8 mice, N=19 endfoot from 8 mice, N=114 processes from 8 mice) and day14 of LPS injection (WT: N= 14 soma from 5 mice, N=11 endfoot from n= 5 mice, N=24 processes from 5 mice. AD: N=12 soma from 5 mice, N=13 endfoot from 6 mice, N=71 processes from 6 mice).

2.3 Ex vivo immunofluorescence analysis of LPS-induced inflammation and $A\beta_{1-42}$ accumulation

To assess neuroinflammation after LPS administration, we harvested brains from subgroups of mouse cohorts for immunofluorescence (IF) staining of GFAP, Iba-1, and Aβ$_{1-42}$ (n = 3 per cohort). We also analyzed a sham group of mice that received 14 days of saline injections (n=3 for AD, n=2 for WT) and an additional group of mice that received 7 days of LPS injection (n=2 for AD, n=3 for WT). Note that the mice received 7 days of LPS injection were not used for *in vivo* imaging. Fig. 5A displays representative confocal images of immunofluorescence staining. We quantified GFAP expression in astrocytes and IBA1 expression in microglia by calculating the percentage area of GFAP and Iba-1 expressed cells in the confocal images (Fig. 5B). In the control group, AD mice showed significantly higher GFAP expression in both cortex and hippocampus compared to WT mice, indicating a pre-existing neuroinflammatory state in AD mice. IBA-1 expression is slightly, but not significantly, higher than in AD control compared to WT control mice. After 7 days of LPS injection, GFAP and IBA1 expression in the WT brain both increased, with a statistically significant increase observed in GFAP expression. Interestingly, GFAP expression in AD astrocytes decreased after 7 days of LPS injection while microglial expression of Iba-1 increased. Iba-1 expression reduced after 14 days in both cohorts. This trend of recovery agrees well with our previous study exploring cortical oxygen extraction during 14 days of LPS injection [32]. The results could reflect immune tolerance induced by the repeated injection of low-dose LPS [33–35]. Fig. 5C shows the representative widefield fluorescence imaging of Aβ$_{1-42}$ in the cortex and hippocampus of AD mice. Strikingly, 14 days of LPS injection yielded reduced $A\beta_{1-42}$ load in AD mice brain, showing statistical significance in cortex and a strong trend in the hippocampus (Fig. 5D). LPS injection induced $A\beta_{1-42}$ reduction was also reported by other studies [36–38]. Higher $A\beta_{1-42}$ load was observed in the cortex compared to hippocampus (Fig. 5D), agreeing well with previous reports in APPswe/PS1dE9 mice [39,40].

Fig. 5. *Ex vivo* immunofluorescence imaging. (A) Representative confocal immunofluorescence image of GFAP and Iba-1expression in barrel cortex and hippocampus in WT and AD mice. Scale bar = 100 μm. **(B)** Quantification of GFAP and IBA-1 expression in barrel cortex and hippocampus. **(C)** Immunofluorescence image of   in AD and WT mice that received 14 days of saline injection, 7 days of LPS injection and 14 days of LPS injection. **(D)** Quantification of   in cerebral cortex and hippocampus. Multiple ROIs were quantified and averaged for each animal (percentage area, mean   sem). One-way ANOVA with Tukey's post hoc test was used in **(B)** and **(D)** to test the difference between saline, 7 days LPS and 14 days LPS injection. Differences between WT and AD saline control group in **(B)** and **(D)** were tested using Student's t test. *p<0.05, **p<0.01, ***p<0.001.

3. DISCUSSION AND CONCLUSION

Our findings demonstrate that amyloid-induced astrocyte reactive alterations disrupt their Ca^{2+}-mediated roles in modulating basal cerebral blood flow and stimulus-evoked functional hyperemia. In 12 to 13-month old female APPswe/PS1dE9 mice and their wildtype littermates, a prolonged 14-day period of LPS-induced systemic inflammation further diminishes Ca^{2+} release from astrocytic soma, processes, and endfeet, and it impairs stimulus-evoked dilation of penetrating arterioles, but not capillaries. Inflammatory disruptions to functional hyperemia are more pronounced for longer stimuli relative to shorter stimuli (30s vs 3s), reflecting the critical roles of astrocytes for sustaining prolonged hyperemic responses, as well as their heightened susceptibility to inflammatory disruptions. For longer periods of functional hyperemia, systemic inflammation induces relatively greater alterations to wildtype mice compared to AD mice.

3.1 Astrocyte Ca^{2+}, microvascular blood flow, and AD

After multiple decades, extensive debates continue regarding the precise contributions of astrocytes for regulating resting state cerebral blood flow and functional hyperemia. In general, resting astrocyte Ca^{2+} is understood to help meet basal metabolic needs by precisely maintaining arteriole diameter. During focal increases in neural activity, glutamate-triggered increases of astrocyte cytosolic Ca^{2+} are believed to stimulate release of vaso-active compounds that modulate arteriole and capillary diameters [27,41–45]. Under different experimental conditions, however, astrocyte Ca^{2+} has been shown to induce both dilation and constriction in arterioles [46]. And multiple studies reported previously that Ca^{2+} released from astrocytic soma occurs too slowly to influence arteriole dilation [47,48]. Conversely, other studies emphasize the significance of faster, previously-undetected astrocyte Ca^{2+} transients in astrocyte endfeet and processes for dilation of arterioles, capillaries, and the contractile sphincters connecting these microvessels [29,30,49–52]. Disparate observations are likely attributable to differences in experimental methodology, age, brain region, stimulus paradigm and frequency, and the presence or absence of anesthesia. Our findings in 12-month old awake female mice support more nuanced assertions that, rather than initiating it, astrocytes contribute to modulation and continuation of the stimulus-evoked hemodynamic response, along with its recovery to baseline levels. Although we observed a more pronounced influence of astrocyte endfeet and processes on arterioles compared to higher-order capillaries, the tradeoffs between imaging speed and imaging area precluded more robust measures of faster, low amplitude Ca^{2+} transients [30,50]. In future studies, improvements in imaging acquisition speed could better delineate the presence and influence these faster Ca^{2+} processes, as well as their prospective variations with AD pathology or systemic inflammation.

In previous studies of AD mouse models, both hyperactive and diminished astrocyte Ca^{2+} signaling have been
reported. The results vary with brain region, disease stage, the presence or absence of a functional stimulus,
and notably, animal model [53–55]. In the absence of induced systemic inflammation, our observations are
consistent with prior reports in APP/PS1 mice that observed increased spontaneous release of cortical
astrocyte $Ca^{2+;}$, [56,57]. Compared to WT control mice, the magnitude of sensory-evoked astrocyte Ca^{2+}
release is larger in AD mice for a brief 3 s whisker stimulus (Fig 1. G-I). However, for a longer 30 s stimulus,
the biphasic responses revealed that astrocytes in the AD mouse brain achieve their maximal Ca^{2+} release
faster than WT mice but, ostensibly, lack sufficient Ca^{2+} stores to sustain the hyperemic response (Fig. 1K-
M). During the latter part of the longer stimulus, we observed that diminished Ca^{2+} release in AD mice
correlates with reduced dilation of penetrating arterioles and capillaries and faster return to baseline diameter.
Our observations agree well with prior studies in anesthetized 6-month old APP/PS1 mice. Lines et al also
observed both increased spontaneous release of Ca^{2+} and decreased evoked astrocyte Ca^{2+} release from 20
seconds of hind-paw stimulation [58]. The precise mechanism(s) of aberrant Ca^{2+} in reactive astrocytes
currently remains inadequately understood. Upregulation of the purinergic and the metabotropic receptors,
increased mitochondria Ca^{2+} efflux, endoplasmic reticulum Ca^{2+} concentration, and variations in neuronal
hyperactivity could all contribute to alterations in spontaneous Ca^{2+} activity within reactive astrocytes [10].
Future studies investigating the internal store concentrations of Ca^{2+} in astrocyte mitochondria and
endoplasmic reticula can clarify their influence on functional hyperemia [59].

Impaired neurovascular coupling has been observed in both AD patients and mouse models, including
Tg2576, J20, and the triple transgenic 3xTg-AD mouse models [53,60–64]. Our OISI and 2-photon
experiments show that APPPS1 mice show mildly reduced stimulus-induced changes to cerebral blood
volume and penetrating arteriole diameter (Fig1.D, F, J). Preserved neurovascular coupling was also reported
in anesthetized J20 mice modeling familial AD at age 9-12 months [65,66]. In high-order capillaries
(diameter < 5 μm), we observed increased resting-state RBC velocity but reduced dilation and faster
relaxation time in response to 30 s stimulus (Supplementary Fig. 2 C&H). Gutiérrez-Jiménez et al. found
reduced resting-state capillary flux and elevated capillary RBC velocity and arteriole dilation induced by 20 s
electrical stimulation evoked in 18-month-old APPswe/PS1dE9 model [67]. Early morphological alterations
in microvasculature have also been reported in APPswe/PS1dE9 mice with electron microscopy [68] and in
3x-Tg mice with optical coherence tomography [69]. Taken together, the current and prior observations
strongly support emerging hypotheses that vascular impairments in AD originate in the microcirculation
before later propagating to larger vessels [70].

3.2 Systemic inflammation's impact on neurovascular coupling and Astrocyte Ca^{2+} signaling

In previous studies with healthy mice and rats, acute periods of LPS-induced systemic inflammation (4-24 hours) yielded substantial reductions in resting state capillary blood flow, cerebral blood volume, and cerebral metabolic rate of oxygen (CMRO$_2$) responses during functional hyperemia [23,71,72]. Here, we showed that a prolonged 14-day period of LPS-induced systemic inflammation provoked mild reductions to baseline diameters of precapillary arterioles and capillaries (Supplementary figure 5) and to vascular dilation for brief 3 s whisker stimulation (Fig. 3, supplementary Fig. 3). We observed more pronounced reductions in arteriole dilation in WT and AD mice in response to longer 30 whisker stimulation (Fig. 4, supplementary Fig. 4). Compared to prior reports, our milder observations can be attributed to the lower dose of LPS (0.3 mg/kg, instead of >1 mg/kg). Additionally, the chronic protocol of low-dose LPS administration (< 1 mg/kg) reportedly induces immune adaptations at later phases in C57BL/6J and APP23 mice, indicated by temporal alterations in pro-inflammatory and anti-inflammatory cytokine expression [34,33,35]. The prior findings suggest a diminishing inflammatory response over several days of LPS administration. Our immunofluorescence results support this phenomenon by showing reduced GFAP expression in astrocytes at day 14 (Fig. 5).

Our findings demonstrate that prolonged inflammation diminishes astrocyte Ca^{2+} dynamics more substantially than microvascular hemodynamics. In astrocytes and other constituents of the neuro-glio-vascular unit, acute periods of LPS-induced inflammation have been shown to elicit notable transcriptional changes, alterations to inflammatory cytokine secretion, and cellular excitability [73–77]. To our knowledge, neither acute nor chronic systemic inflammation's influence on astrocyte Ca^{2+} signaling have been investigated previously. In both AD and WT mice, we observed persistent, compartment-specific reductions in astrocyte Ca^{2+} release under resting state and during functional stimulation. Again, LPS-induced reductions to stimulus-evoked astrocyte Ca^{2+} were more severe for a longer functional stimulus in both AD and WT mice, indicating that a secondary inflammatory threat further compromises the internal store concentrations of Ca^{2+} in astrocytes of AD mice.

Our study compellingly support the hypothesis that AD pathology increases astrocytes' susceptibility to a secondary inflammatory challenge [73]. Our results highlight the significant, critical link between inflammatory and vascular impairments of preclinical AD pathology and the detrimental "second hit" impact imposed by an acute period of illness. Importantly, Ca^{2+} signaling also reportedly regulates astrocytic inflammatory processes by driving NFAT- and NFκB- mediated transcription. Future studies will focus on the role of astrocyte Ca^{2+} as the bidirectional link between neuroinflammation and cerebral blood flow in AD pathogenesis, as well as its role in augmenting astrocyte phagocytosis of Aβ$_{1-42}$ (Fig. 5) [37,78,36,38,7].

DECLARATION OF INTERESTS

The authors declare no competing interests.

ACKNOWLEDGMENTS

This work was performed with generous support from the Northeastern College of Engineering and the National Institutes of Health: NIH R01AA27097, NIH R56AG058849, and R21AG085655. We thank Dr. Martin Thunemann and John Jiang from Boston University for their guidance with animal surgery and calcium imaging. We thank Dr. Guoxin Rong and the Institute for Chemical Imaging of Living Systems (RRID:SCR_022681) at Northeastern University for consultation and imaging support, and for the assistance of confocal imaging and wide-field fluorescence imaging. We thank Dana-Farber/Harvard Cancer Center in Boston, MA, for the use of the Specialized Histopathology Core, which provided brain slices immunofluorescence staining service. Dana-Farber/Harvard Cancer Center is supported in part by an NCI Cancer Center Support Grant # NIH 5 P30 CA06516.

4. METHODS

4.1 Animal preparation

All experiments were performed following ARRIVE guidelines for animal care, under a protocol approved by the Northeastern University Institutional Animal Care and Use Committee. The mouse strain used for this research project, B6C3-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax, RRID:MMRRC_034829-JAX, was obtained from the Mutant Mouse Resource and Research Center (MMRRC) at The Jackson Laboratory, an NIH-funded strain repository, and was donated to the MMRRC by David Borchelt, Ph.D., McKnight Brain Institute, University of Florida. The double transgenic AD mouse co-expresses the Swedish mutation of amyloid precursor protein (APP) and a mutant human presenilin 1 gene (PS1-dE9) and accumulates beta-amyloid deposits in the cortex at 6 months [1]. The study used female APP/PS1dE9 mice and their wild-type littermates (age 12-13 months, n=8 per cohort). At 10 months of age, mice underwent cranial window surgery followed by GFAP-promoted GCaMP6f virus injection. Under isoflurane anesthesia (3–3.5% isoflurane for induction and 1–2% for maintenance), hair and skin was removed to expose the skull, and a titanium butterfly-shaped head post was implanted using dental cement [80]. After the localization of the injection

site, a ~ 3 mm diameter of cranial window was created on the barrel cortex of the mouse, followed by
targeted injection of a GFAP-promoted GCaMP6f virus (pZac2.1gfaABC1D-cyto-GCaMP6f, Plasmid
#52925, Addgene). Virus (300–500 nL) was injected at 2 nL/s, 300–350 μm below the brain surface, using a
glass micropipette and a Nanoinjector III (Drummond Scientific) [81]. Injections were performed in two to
three cortical regions to increase the area of viral expression. The procedure lasted 15 to 20 minutes, with the
dura kept hydrated throughout. After the injections, the dura was covered with a CNC-machined transparent
acrylic coverslip (outer diameter: 5 mm, inner diameter: 3 mm). The mouse was then removed from the
stereotaxic frame and allowed to recover from anesthesia. The animal was single-housed and provided with 5
days of post-operative care (40mg/ml sulfamethoxazole (SMX) and 8 mg/ml trimethoprim (TMP) in drinking
water). Buprenorphine (0.05 mg/kg at 0.03 mg/ml) was administered subcutaneously for three days after
surgery. To label astrocytes in the activation center, we conducted optical intrinsic signal imaging (OISI) and
whisker stimulation on the anesthetized mouse before removing the skull. The skull over the barrel cortex (A-
P: 2mm, M-L: 3 mm) was thinned, and whiskers on the contralateral side of the thinned skull were deflected
using a cotton swab. The skull was illuminated with an LED light source during the stimulation through a
green bandpass filter (568/10 nm). The reflected light was recorded with a CMOS camera (Basler acA1300–
$200\mu m$, Edmund optics) mounted on the surgical microscope, and the relative intensity change was calculated
with a customized MATLAB script. Regions with the greatest intensity drop were identified as the activation
area and selected as the site for viral injection.

4.2 Habituation training

Headpost restraint training started 7 to 10 days post-surgery using a custom-made imaging cradle. During
training, the mouse was conditioned to tolerate head immobilization from 5 minutes to 1 hour. Whisker
stimulation was included during the final training sessions to acclimate the animal to the functional activation
experiment. Milk was given as a reward during the training.

4.3 Systemic inflammation induction

Peripheral inflammation induced by systemic injection of LPS has been shown to transfer to the central
nervous system and cause a prolonged inflammatory response in the brain [82]. Systemic inflammation was
induced through daily intraperitoneal (i.p.) injections of 0.3 mg/kg lipopolysaccharide (LPS, *E. coli* O55: B5,
L4005, CAS-No. 93572-42-0, Sigma-Aldrich) for 14 days. A stock solution of LPS was prepared at 1mg/mL
in phosphate-buffered saline (PBS) and stored at -20°C. The solution was vortexed and diluted 4-fold to 0.25
mg/mL for each injection.

4.4 Functional activation protocol

A capillary tube with a 3D-printed broom-like end was positioned approximately 2.5–3 cm from the nose, parallel to the right side of the mouse's face, and below the eye to avoid directing air toward the eyes during stimulation. Air puffs were delivered through the tube and controlled using a pneumatic drug injection system (PDES-DXH, ALA Scientific, USA). Two whisker stimulation protocols—brief and prolonged—were performed. The brief protocol consisted of a 5-second baseline, 2.7 seconds of 1.67 Hz stimulation (5 pulses, 20 psi), and 22.3 seconds of recovery. The prolonged protocol included a 5-second baseline, 30 seconds of 1.67 Hz stimulation (50 pulses, 20 psi), and 30 seconds of recovery. Short and long stimulations were interleaved within each trial and repeated 10 times.

4.5 Functional activation center mapping

The activation center of whisker stimulation was mapped using optical intrinsic signal imaging (OISI) under the brief whisker stimulation protocol. A white LED illuminator (SCHOTT KL 1600) with a 568/10 nm bandpass filter (Edmund Optics) served as the light source. The camera was triggered by a TTL signal from a general-purpose input/output (GPIO) hardware trigger. A fiber-optic LED light source illuminator (SCHOTT KL 1600 LED) delivered light to the cranial window at a 60° angle. Reflected light was collected using a 4× objective (Nikon Instruments Inc.) and recorded at 5 Hz for 20 seconds with a CMOS camera (Basler acA1300–200μm, Edmund Optics). Baseline intensity (I_0) was calculated by averaging the intensity over the baseline recording. Relative intensity (I/I_0) was calculated for all imaging frames. Cortical area with the maximal intensity decreases was identified as the activation center.

4.6 Two-photon imaging in awake mice

Two-photon imaging of astrocyte Ca^{2+} signaling and vascular dynamics at barrel cortex at resting-state and during functional activation was conducted using the multiphoton imaging system Ultima2pPlus (Bruker Nano, Inc) with a 25× objective (1.10 NA, Nikon Instruments Inc). Imaging during the functional activation experiment was synchronized with the whisker stimulation protocol. Blood vessels were labeled through retro-orbital injection of Texas Red Dextran (2.5% w/v, 80uL). A tunable ultrafast laser (InSight X3+, Spectral-Physics) was tuned to 940 nm for simultaneous imaging of blood vessels and astrocytic Ca^{2+} imaging. We tracked the penetrating arterioles from the pial surface to the deepest assessable cortical layer and recorded the vessel diameter and the astrocyte Ca^{2+} release using a minimal frame rate of 4.3 Hz. The image field of view (FOV) was around $88 \times 88\ um^2$. On the following day, capillary diameter and red blood cell velocity in response to the interleaved functional activation was measured with two-photon line scanning [83], with a scan frequency ranging from 369.87 to 1034.8 Hz. Penetrating arterioles perpendicular to the image plane and capillaries parallel to it were selected to ensure accurate diameter estimation, while

461 tilted vessels were excluded during post-processing. We measured regions from 49 to 414 μm below the pial

462 surface for WT mice and 30 to 360 μm below the pial surface for AD mice.

4.7 Two-photon imaging data analysis

Astrocyte spontaneous Ca^{2+}: Image frames were pre-processed using a non-rigid motion correction

algorithm [84], followed by median filtering. Resting-state astrocyte Ca^{2+} fluctuations were quantified using a

ROI-based Ca^{2+} analysis tool: "GECIquant" in ImageJ [85]. Briefly, average intensity projection was

generated from the time series of two-photon raster scan images. We created a binary region of interest (ROI)

mask where the area within the polygon ROI was set to 1 and the pixels in the rest of the image was set to 0.

Mean intensity within the ROI over time was calculated. The area criterion was set to $30\ \mu m^2$ to Inf for

astrocyte soma and endfeet, and 8 to 2000 μm^2 for Ca^{2+} waves in processes. Relative intensity change

$(\Delta F/F_0 = (F_t - F_0)/F_0)$ was calculated. F_0 was calculated as the median of the lowest 5% fluorescence

intensity over the entire 10-minute raster scan. $\Delta F/F_0$ of all astrocyte ROIs from all mice were interpolated

with a $dt = 0.2244\ s$, (i.e., 4.45 fps). The $\Delta F/F_0$ traces were pre-processed using linear detrending to

remove intensity drift that occurred during the measurement. The detrended intensity traces were then low

pass filtered with a cutoff frequency of 0.1 Hz, as determined by power spectrum analysis. To determine the

threshold for the Ca^{2+} event, we sorted the normalized intensity values in ascending order, calculated the

median absolute deviation (MAD) of the lowest 80% of the $\Delta F/F$ values, and used 5 times the MAD as the

threshold for the Ca^{2+} event. This threshold is robust to outliers and helps to reduce the number of 'false

positives'. Ca^{2+} events were detected and quantified using the 'findpeaks' function in MATLAB. The detected

events were categorized as either 'singlepeak' or 'multipeak' events as described [86]. We calculated the

frequency of the event as per min per ROI.

Arteriole diameter: Arteriole diameter in response to functional activation was quantified using the automatic

structure tracking algorithm developed by Haidey et al. [87]. The algorithm tracks the cross-sectional area of

the vessel based on user-defined luminal edges. Vessel diameter (D) was calculated from the cross-sectional

area. Relative change of diameter ($\Delta D/D_0 = (D_t - D_0)/D_0 \times 100$) was calculated, where the baseline

diameter (D_0) was the average diameter over the 5s resting-state measurement. Since the frame rates of

different imaging fields sometimes vary slightly, $\Delta D/D_0$ were interpolated with $\Delta t = 0.2244\ s$.

Quantifying stimulus-evoked responses: To quantify stimulus-evoked arteriole dilation and astrocyte Ca^{2+}

release, we first scrutinized all 10 stimulation trials and excluded those with motion artifacts. The remaining

trials were classified as either 'with response' or 'without response.' Trials exhibiting responses were

averaged to determine the mean $\Delta D/D0$ (arteriole dilation) and $\Delta F/F0$ (Ca^{2+} activity) for each region of

interest (ROI). The averaged arteriole dilation and Ca^{2+} signals were low-pass filtered with a cutoff frequency

of 0.2 Hz. Peak responses were identified using the 'findpeaks' function in MATLAB. For each detected

peak, the amplitude and latency were calculated. Peak latency was defined as the time interval between

stimulus onset and the peak response. The area under the curve (AUC) was calculated for each stimulation

paradigm, as reported by previous publication [28]. For 3s whisker stimulation, AUC was computed over the

0–25 s window, while for 30s stimulation, it was assessed over 0–60 s. Additionally, for 30s stimulation, the

average response during the last 2s of stimulation was calculated to assess late phase activity. To analyze

response kinetics, we followed the method used in a recent publication to fit $\Delta D/D\square$ and $\Delta F/F\square$ traces with a

sigmoidal model [88]. The rise part of the trace was fitted using the equation $f(x) = \frac{a}{1+e^{-b(x-c)}}$, and the decay

part of the trace was fitted using the 4-parameter logistic equation $f(x) = d + \frac{a-d}{1+\left(\frac{x}{c}\right)^{b}}$. Rise time was

calculated as the interval between 10% and 90% of the fitted peak response amplitude. Fall time was

determined as the time required for the signal to decay from 90% to 10% of the peak response in the fitted

curve. Duration was calculated as the full width half maximum (FWHM). Note that responses to 30s

stimulation have a plateau phase, the decay part of the traces was defined when the responsive trace start to

return to the baseline. Duration for 30s stimulation is determined as the time interval from the half-maximal

of the rising phase to the half-maximal of the decay phase.

Capillary diameter: Space-time images from two-photon line scans were denoised using a 2D median filter.

Vessel diameter was calculated using the MATLAB two-photon imaging analysis toolbox, CHIPS [89]. The

algorithm normalizes the vessel's intensity profile to a range of 0 to 1 and calculates the diameter using the

full width at a user-defined height. We used the full width at 0.4 of the maximum intensity, as it provided the

most robust diameter estimation based on our signal-to-background ratio. The sampling rate was set at a

maximum of 20 Hz. Measurements affected by motion, particularly along the axial axis were discarded.

Average diameter and $\Delta D/D\square$ across all selected stimulation trials were calculated. The $\Delta D/D\square$ traces were

smoothed using a moving median filter with a one-second window (20 data points). Vascular dilation

amplitude, AUC and kinetics were analyzed using the same method as in raster-scan data analysis. Vessels

were categorized by branch order: penetrating arterioles (0th-order), pre-capillary arterioles (1st and 2[nd]order),

and higher-order capillaries (>3rd-order branches). Resting-state capillary diameter was calculated by

averaging the baseline measurement taken from 1.5 s to 4.5s.

Capillary RBC velocity: The space-time images were filtered using Sobel filtering, and the capillary red blood

cell (RBC) velocity was analyzed using the iterative Radon Transform [90]. Image segments of every 100

lines were used to calculate RBC velocity. 25 lines were skipped before calculating the velocity at the next

time point, leading to a time window of the RBC velocity from 24 ms to 67 ms. Relative velocity ($\Delta v/v\square$,%)

was calculated and filtered with a low-pass filter with a cut off frequency of 0.1 Hz. All Δv/v□ traces were

interpolated with dt = 0.05s.

Line scan measurement of astrocyte Ca^2 : Line segment measuring the astrocyte processes and endfoot

wrapping around the capillaries were selected during post-processing. Total intensity along the line was

calculated and normalized to ΔF/F0 (%). The normalized intensity traces were also downsampled to 20Hz.

Amplitude, AUC and kinetics were quantified.

4.8 Ex vivo immunofluorescence imaging (IF)

After 14 days of LPS treatment, mice were sacrificed, and brains were collected for immunofluorescence (IF)

staining. IF staining was performed on a subset of the imaged mice (n=3 per cohort). Mice received 14 days

of saline injections at a volume equivalent to the LPS dose of 0.3 mg/kg served as control group (n=2 for WT,

n=3 for AD). A separate group of mice received 7 days of LPS injection was used as well (n=2 for AD, n=3

for WT). Mice were intracardially perfused with 40 mL of heparin-PBS solution, followed by 20 mL of 4%

paraformaldehyde (PFA) for fixation. The brains were collected and stored in 4% PFA for a maximum of 24

hours, then transferred to 70% ethanol and stored in $-4\ ℃$ fridge. The brain samples were sent to the Dana-

Farber/Harvard Cancer Center Specialized Histopathology Services Core (Boston, MA, USA) for

immunofluorescence staining. The samples were paraffin-embedded and sliced into approximately 10 μm

thick sections for IF staining. Nuclei were stained with DAPI, microglia with an anti-Iba-1 antibody labeled

with Alexa Fluor 594, and astrocytes with an anti-GFAP antibody labeled with Alexa Fluor 647. IF images

were collected with confocal microscopy (LSM 800, ZEISS). DAPI, AF-647, and AF-594 were excited with

405nm, 640nm, and 561nm, respectively. Images were taken using 5× and 10× objectives. Barrel cortex and

hippocampus were identified using the Allen Brain Atlas. For each 10× field of view ($638\ \times\ 638\ um^2$), Z-

stack images were collected with a step size of $0.34\ \mu m$. All images were acquired using consistent excitation

power and emission detector gain settings. $Aβ_{1-42}$ was stained with anti-$Aβ_{1-42}$ antibody conjugated to Alexa

Fluor 647. Fluorescence images of $Aβ_{1-42}$ were acquired with wide-field fluorescence microscopy (Zeiss Axio

Observer). All images were acquired using the same exposure time.

GFAP and Iba-1 expression were quantified using the maximum intensity projection (MIP) of the z-series

images. Background was removed and MIP images were binarized using an intensity threshold. The

percentage area of pixels with intensity above the intensity threshold was calculated. Similarly, percentage

area of $Aβ_{1-42}$ load in cortex and hippocampus was quantified in Image J.

4.9 Statistical analysis

We performed statistical tests to see if there is difference in spontaneous astrocyte Ca^{2+} dynamics, stimulus-

evoked vessel dilation and astrocyte Ca^{2+} release in AD, and how LPS-induced systemic inflammation affects

these parameters in both WT and AD cohorts. Differences between WT and AD group before LPS injection

were tested using the Wilcoxon rank sum test on MATLAB. Effect of LPS on both cohorts were tested using

linear mixed effect model with the 'lme4' package in RStudio. Time (i.e., day0, day 7 and day14) was set as

the fixed effect. Pair-wise comparison was conducted with Tukey's method in the 'emmeans' package. * =

$p<0.05$, ** = $p<0.01$, ***=$p<0.001$, ****=$p<0.0001$.

REFERENCES

1. V. Calsolaro and P. Edison, "Neuroinflammation in Alzheimer's disease: Current evidence and future directions," Alzheimer's & Dementia **12**, 719–732 (2016).
2. M. T. Heneka, M. J. Carson, J. E. Khoury, G. E. Landreth, F. Brosseron, D. L. Feinstein, A. H. Jacobs, T. Wyss-Coray, J. Vitorica, R. M. Ransohoff, K. Herrup, S. A. Frautschy, B. Finsen, G. C. Brown, A. Verkhratsky, K. Yamanaka, J. Koistinaho, E. Latz, A. Halle, G. C. Petzold, T. Town, D. Morgan, M. L. Shinohara, V. H. Perry, C. Holmes, N. G. Bazan, D. J. Brooks, S. Hunot, B. Joseph, N. Deigendesch, O. Garaschuk, E. Boddeke, C. A. Dinarello, J. C. Breitner, G. M. Cole, D. T. Golenbock, and M. P. Kummer, "Neuroinflammation in Alzheimer's disease," The Lancet Neurology **14**, 388–405 (2015).
3. C. Iadecola, "Neurovascular regulation in the normal brain and in Alzheimer's disease," Nat Rev Neurosci **5**, 347–360 (2004).
4. B. V. Zlokovic, "Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders," Nat Rev Neurosci **12**, 723–738 (2011).
5. E. Colombo and C. Farina, "Astrocytes: Key Regulators of Neuroinflammation," Trends in Immunology **37**, 608–620 (2016).
6. A. Lia, A. Di Spiezio, M. Speggiorin, and M. Zonta, "Two decades of astrocytes in neurovascular coupling," Front. Netw. Physiol. **3**, 1162757 (2023).
7. M. M. Novakovic and M. Prakriya, "Calcium signaling at the interface between astrocytes and brain inflammation," Current Opinion in Neurobiology **90**, 102940 (2025).
8. C. Iadecola, "The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease," Neuron **96**, 17–42 (2017).
9. E. C. Kugler, J. Greenwood, and R. B. MacDonald, "The "Neuro-Glial-Vascular" Unit: The Role of Glia in Neurovascular Unit Formation and Dysfunction," Front. Cell Dev. Biol. **9**, (2021).
10. E. Shigetomi, K. Saito, F. Sano, and S. Koizumi, "Aberrant Calcium Signals in Reactive Astrocytes: A Key Process in Neurological Disorders," Int J Mol Sci **20**, 996 (2019).
11. A. Verkhratsky, "Astroglial Calcium Signaling in Aging and Alzheimer's Disease," Cold Spring Harb Perspect Biol **11**, a035188 (2019).
12. G. R. Frost and Y.-M. Li, "The role of astrocytes in amyloid production and Alzheimer's disease," Open Biol. **7**, 170228 (2017).
13. D. Shah, W. Gsell, J. Wahis, E. S. Luckett, T. Jamoulle, B. Vermaercke, P. Preman, D. Moechars, V. Hendrickx, T. Jaspers, K. Craessaerts, K. Horré, L. Wolfs, M. Fiers, M. Holt, D. R. Thal, Z. Callaerts-Vegh, R. D'Hooge, R. Vandenberghe, U. Himmelreich, V. Bonin, and B. De Strooper, "Astrocyte calcium dysfunction causes early network hyperactivity in Alzheimer's disease," Cell Reports **40**, 111280 (2022).
14. M. T. Heneka, W. M. van der Flier, F. Jessen, J. Hoozemanns, D. R. Thal, D. Boche, F. Brosseron, C. Teunissen, H. Zetterberg, A. H. Jacobs, P. Edison, A. Ramirez, C. Cruchaga, J.-C. Lambert, A. R. Laza, J. V. Sanchez-Mut, A. Fischer, S. Castro-Gomez, T. D. Stein, L. Kleineidam, M. Wagner, J. J. Neher, C. Cunningham, S. K. Singhrao, M. Prinz, C. K. Glass, J. C. M. Schlachetzki, O. Butovsky, K. Kleemann, P. L. De Jaeger, H. Scheiblich, G. C. Brown, G. Landreth, M. Moutinho, J. Grutzendler, D. Gomez-Nicola, R. M. McManus, K. Andreasson, C. Ising, D. Karabag, D. J. Baker, S. A. Liddelow, A. Verkhratsky, M. Tansey, A. Monsonego, L. Aigner, G. Dorothée, K.-A. Nave, M. Simons, G. Constantin, N. Rosenzweig, A. Pascual, G. C. Petzold, J. Kipnis, C. Venegas, M. Colonna, J. Walter, A. J. Tenner, M. K. O'Banion, J. R. Steinert, D. L. Feinstein, M. Sastre, K. Bhaskar, S. Hong, D. P. Schafer, T. Golde, R. M. Ransohoff, D. Morgan, J. Breitner, R. Mancuso, and S.-P. Riechers, "Neuroinflammation in Alzheimer disease," Nat Rev Immunol **25**, 321–352 (2025).
15. Y. Liu, Y. Tan, Z. Zhang, H. Li, M. Yi, Z. Zhang, S. Hui, and W. Peng, "Neuroimmune mechanisms underlying Alzheimer's disease: Insights into central and peripheral immune cell crosstalk," Ageing Research Reviews **84**, 101831 (2023).
16. S. C. Weninger and B. A. Yankner, "Inflammation and Alzheimer disease: The good, the bad, and the ugly," Nat. Med. **7**, 527–528 (2001).
17. F. Sardi, L. Fassina, L. Venturini, M. Inguscio, F. Guerriero, E. Rolfo, and G. Ricevuti, "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly," Autoimmunity Reviews **11**, 149–153 (2011).
18. M. E. Lull and M. L. Block, "Microglial activation and chronic neurodegeneration," Neurotherapeutics **7**, 354–365 (2010).

19. J. van Horssen, P. van Schaik, and M. Witte, "Inflammation and mitochondrial dysfunction: A vicious circle in neurodegenerative disorders?," Neurosci Lett **710**, 132931 (2019).

20. J. W. Lee, Y. K. Lee, D. Y. Yuk, D. Y. Choi, S. B. Ban, K. W. Oh, and J. T. Hong, "Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation," J Neuroinflammation **5**, 37 (2008).

21. D. T. Skelly, É. W. Griffin, C. L. Murray, S. Harney, C. O'Boyle, E. Hennessy, M.-A. Dansereau, A. Nazmi, L. Tortorelli, J. N. Rawlins, D. M. Bannerman, and C. Cunningham, "Acute transient cognitive dysfunction and acute brain injury induced by systemic inflammation occur by dissociable IL-1-dependent mechanisms," Mol Psychiatry **24**, 1533–1548 (2019).

22. A. M. Birch, L. Katsouri, and M. Sastre, "Modulation of inflammation in transgenic models of Alzheimer's disease," Journal of Neuroinflammation **11**, 25 (2014).

23. S. K. Fruekilde, C. J. Bailey, K. L. Lambertsen, B. H. Clausen, J. Carlsen, N. Xu, K. R. Drasbek, and E. Gutiérrez-Jiménez, "Disturbed microcirculation and hyperaemic response in a murine model of systemic inflammation," J Cereb Blood Flow Metab 0271678X2211122 (2022).

24. L. E. Evans, J. L. Taylor, C. J. Smith, H. A. T. Pritchard, A. S. Greenstein, and S. M. Allan, "Cardiovascular comorbidities, inflammation, and cerebral small vessel disease," Cardiovascular Research cvab284 (2021).

25. S. B. Sankar, A. F. Pybus, A. Liew, B. Sanders, K. J. Shah, L. B. Wood, and E. M. Buckley, "Low cerebral blood flow is a non-invasive biomarker of neuroinflammation after repetitive mild traumatic brain injury," Neurobiol Dis **124**, 544–554 (2019).

26. C. R. A. Batista, G. F. Gomes, E. Candelario-Jalil, B. L. Fiebich, and A. C. P. de Oliveira, "Lipopolysaccharide-Induced Neuroinflammation as a Bridge to Understand Neurodegeneration," IJMS **20**, 2293 (2019).

27. A. Mishra, G. R. Gordon, B. A. MacVicar, and E. A. Newman, "Astrocyte Regulation of Cerebral Blood Flow in Health and Disease," Cold Spring Harb Perspect Biol **16**, a041354 (2024).

28. A. Institoris, M. Vandal, G. Peringod, C. Catalano, C. H. Tran, X. Yu, F. Visser, C. Breiteneder, L. Molina, B. S. Khakh, M. D. Nguyen, R. J. Thompson, and G. R. Gordon, "Astrocytes amplify neurovascular coupling to sustained activation of neocortex in awake mice," Nat Commun **13**, 7872 (2022).

29. Y. Otsu, K. Couchman, D. G. Lyons, M. Collot, A. Agarwal, J.-M. Mallet, F. W. Pfrieger, D. E. Bergles, and S. Charpak, "Calcium dynamics in astrocyte processes during neurovascular coupling," Nat Neurosci **18**, 210–218 (2015).

30. B. L. Lind, A. R. Brazhe, S. B. Jessen, F. C. C. Tan, and M. J. Lauritzen, "Rapid stimulus-evoked astrocyte Ca^{2+} elevations and hemodynamic responses in mouse somatosensory cortex in vivo," Proceedings of the National Academy of Sciences **110**, E4678–E4687 (2013).

31. P. Blinder, P. S. Tsai, J. P. Kaufhold, P. M. Knutsen, H. Suhl, and D. Kleinfeld, "The cortical angiome: an interconnected vascular network with noncolumnar patterns of blood flow," Nat Neurosci **16**, 889–897 (2013).

32. C. Liu, A. Cárdenas-Rivera, S. Teitelbaum, A. Birmingham, M. Alfadhel, and M. A. Yaseen, "Neuroinflammation increases oxygen extraction in a mouse model of Alzheimer's disease," Alz Res Therapy **16**, 78 (2024).

33. J. Kim, O. Sullivan, K. Lee, J. Jao, J. Tamayo, A. M. Madany, B. Wong, P. Ashwood, and A. V. Ciernia, "Repeated LPS induces training and tolerance of microglial responses across brain regions," J Neuroinflammation **21**, 233 (2024).

34. A.-C. Wendeln, K. Degenhardt, L. Kaurani, M. Gertig, T. Ulas, G. Jain, J. Wagner, L. M. Häsler, K. Wild, A. Skodras, T. Blank, O. Staszewski, M. Datta, T. P. Centeno, V. Capece, Md. R. Islam, C. Kerimoglu, M. Staufenbiel, J. L. Schultze, M. Beyer, M. Prinz, M. Jucker, A. Fischer, and J. J. Neher, "Innate immune memory in the brain shapes neurological disease hallmarks," Nature **556**, 332–338 (2018).

35. D. M. Norden, P. J. Trojanowski, E. Villanueva, E. Navarro, and J. P. Godbout, "Sequential activation of microglia and astrocyte cytokine expression precedes increased iba 1 or GFAP immunoreactivity following systemic immune challenge," Glia **64**, 300–316 (2016).

36. C. Thygesen, L. Ilkjær, S. J. Kempf, A. L. Hemdrup, C. U. von Linstow, A. A. Babcock, S. Darvesh, M. R. Larsen, and B. Finsen, "Diverse Protein Profiles in CNS Myeloid Cells and CNS Tissue From Lipopolysaccharide- and Vehicle-Injected APPSWE/PS1ΔE9 Transgenic Mice Implicate Cathepsin Z in Alzheimer's Disease," Front. Cell. Neurosci. **12**, 397 (2018).

37. T. M. Malm, M. Koistinaho, M. Pärepalo, T. Vatanen, A. Ooka, S. Karlsson, and J. Koistinaho, "Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to β-amyloid deposition in APP/PS1 double transgenic Alzheimer mice," Neurobiology of Disease **18**, 134–142 (2005).

38. C. Jendresen, A. Digre, H. Cui, X. Zhang, I. Vlodavsky, J.-P. Li, and L. N. G. Nilsson, "Systemic LPS-induced Aβ-solubilization and clearance in AβPP-transgenic mice is diminished by heparanase overexpression," Sci Rep **9**, 4600 (2019).

39. C. U. Von Linstow, J. Waider, M. Grebing, A. Metaxas, K. P. Lesch, and B. Finsen, "Serotonin augmentation therapy by escitalopram has minimal effects on amyloid-β levels in early-stage Alzheimer's-like disease in mice," Alz Res Therapy **9**, 74 (2017).

40. A. Willuweit, M. Schöneck, S. Schemmert, P. Lohmann, S. Bremen, D. Honold, N. Burda, N. Jiang, S. Beer, J. Ermert, D. Willbold, N. J. Shah, and K.-J. Langen, "Comparison of the Amyloid Load in the Brains of Two Transgenic Alzheimer's Disease Mouse Models Quantified by Florbetaben Positron Emission Tomography," Front. Neurosci. **15**, 699926 (2021).

41. A. Lia, A. Di Spiezio, M. Speggiorin, and M. Zonta, "Two decades of astrocytes in neurovascular coupling," Front Netw Physiol **3**, 1162757 (2023).

42. D. G. Rosenegger, C. H. T. Tran, J. I. W. Cusulin, and G. R. Gordon, "Tonic Local Brain Blood Flow Control by Astrocytes Independent of Phasic Neurovascular Coupling," J. Neurosci. **35**, 13463–13474 (2015).

43. K. J. Kim, J. A. Iddings, J. E. Stern, V. M. Blanco, D. Croom, S. A. Kirov, and J. A. Filosa, "Astrocyte Contributions to Flow/Pressure-Evoked Parenchymal Arteriole Vasoconstriction," J. Neurosci. **35**, 8245–8257 (2015).

44. F. Tesler, M.-L. Linne, and A. Destexhe, "Modeling the relationship between neuronal activity and the BOLD signal: contributions from astrocyte calcium dynamics," Sci Rep **13**, 6451 (2023).

45. N. Bazargani and D. Attwell, "Astrocyte calcium signaling: the third wave," Nat Neurosci **19**, 182–189 (2016).

46. G. R. J. Gordon, H. B. Choi, R. L. Rungta, G. C. R. Ellis-Davies, and B. A. MacVicar, "Brain metabolism dictates the polarity of astrocyte control over arterioles," Nature **456**, 745–749 (2008).

47. K. Nizar, H. Uhlirova, P. Tian, P. A. Saisan, Q. Cheng, L. Reznichenko, K. L. Weldy, T. C. Steed, V. B. Sridhar, C. L. MacDonald, J. Cui, S. L. Gratiy, S. Sakadzic, D. A. Boas, T. I. Beka, G. T. Einevoll, J. Chen, E. Masliah, A. M. Dale, G. A. Silva, and A. Devor, "In vivo Stimulus-Induced Vasodilation Occurs without IP3 Receptor Activation and May Precede Astrocytic Calcium Increase," Journal of Neuroscience **33**, 8411–8422 (2013).

48. D. E. Bonder and K. D. McCarthy, "Astrocytic Gq-GPCR-linked IP3R-dependent Ca2+ signaling does not mediate neurovascular coupling in mouse visual cortex in vivo," J Neurosci **34**, 13139–13150 (2014).

49. A. Lia, V. J. Henriques, M. Zonta, A. Chiavegato, G. Carmignoto, M. Gómez-Gonzalo, and G. Losi, "Calcium Signals in Astrocyte Microdomains, a Decade of Great Advances," Front. Cell. Neurosci. **15**, (2021).

50. B. L. Lind, S. B. Jessen, M. Lønstrup, C. Joséphine, G. Bonvento, and M. Lauritzen, "Fast Ca2+ responses in astrocyte end-feet and neurovascular coupling in mice," Glia **66**, 348–358 (2018).

51. X. Gu, W. Chen, N. D. Volkow, A. P. Koretsky, C. Du, and Y. Pan, "Synchronized Astrocytic Ca2+ Responses in Neurovascular Coupling during Somatosensory Stimulation and for the Resting State," Cell Reports **23**, 3878–3890 (2018).

52. B. Lind and A. Volterra, "Fast 3D imaging in the auditory cortex of awake mice reveals that astrocytes control neurovascular coupling responses at arteriole-capillary junctions.," (2025).

53. A. Lia, G. Sansevero, A. Chiavegato, M. Sbrissa, D. Pendin, L. Mariotti, T. Pozzan, N. Berardi, G. Carmignoto, C. Fasolato, and M. Zonta, "Rescue of astrocyte activity by the calcium sensor STIM1 restores long-term synaptic plasticity in female mice modelling Alzheimer's disease," Nat Commun **14**, 1590 (2023).

54. M. J. Berridge, "Calcium hypothesis of Alzheimer's disease," Pflugers Arch - Eur J Physiol **459**, 441–449 (2010).

55. D. Shah, W. Gsell, J. Wahis, E. S. Luckett, T. Jamoulle, B. Vermaercke, P. Preman, D. Moechars, V. Hendrickx, T. Jaspers, K. Craessaerts, K. Horré, L. Wolfs, M. Fiers, M. Holt, D. R. Thal, Z. Callaerts-Vegh, R. D'Hooge, R. Vandenberghe, U. Himmelreich, V. Bonin, and B. De Strooper, "Astrocyte calcium dysfunction causes early network hyperactivity in Alzheimer's disease," Cell Reports **40**, 111280 (2022).

56. K. V. Kuchibhotla, C. R. Lattarulo, B. T. Hyman, and B. J. Bacskai, "Synchronous Hyperactivity and Intercellular Calcium Waves in Astrocytes in Alzheimer Mice," Science **323**, 1211–1215 (2009).

57. A. Delekate, M. Füchtemeier, T. Schumacher, C. Ulbrich, M. Foddis, and G. C. Petzold, "Metabotropic P2Y1 receptor signalling mediates astrocytic hyperactivity in vivo in an Alzheimer's disease mouse model," Nat Commun **5**, 5422 (2014).

58. J. Lines, A. M. Baraibar, C. Fang, E. D. Martin, J. Aguilar, M. K. Lee, A. Araque, and P. Kofuji, "Astrocyte□neuronal network interplay is disrupted in Alzheimer's disease mice," Glia **70**, 368–378 (2022).

59. J. Suzuki, K. Kanemaru, K. Ishii, M. Ohkura, Y. Okubo, and M. Iino, "Imaging intraorganellar Ca2+ at subcellular resolution using CEPIA," Nat Commun **5**, 4153 (2014).

60. Y. Iturria-Medina, R. C. Sotero, P. J. Toussaint, J. M. Mateos-Pérez, A. C. Evans, and Alzheimer's Disease Neuroimaging Initiative, "Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis," Nat Commun **7**, 11934–11934 (2016).

61. S. Tarantini, C. H. T. Tran, G. R. Gordon, Z. Ungvari, and A. Csiszar, "Impaired neurovascular coupling in aging and Alzheimer's disease: Contribution of astrocyte dysfunction and endothelial impairment to cognitive decline," Experimental Gerontology **94**, 52–58 (2017).

62. L. Park, J. Zhou, K. Koizumi, G. Wang, A. Anfray, S. J. Ahn, J. Seo, P. Zhou, L. Zhao, S. Paul, J. Anrather, and C. Iadecola, "tPA Deficiency Underlies Neurovascular Coupling Dysfunction by Amyloid-β," J. Neurosci. **40**, 8160–8173 (2020).

63. L. Li, X.-K. Tong, M. Hosseini Kahnouei, D. Vallerand, E. Hamel, and H. Girouard, "Impaired Hippocampal Neurovascular Coupling in a Mouse Model of Alzheimer's Disease," Front. Physiol. **12**, 715446 (2021).

64. C. F. Lourenço, A. Ledo, R. M. Barbosa, and J. Laranjinha, "Neurovascular uncoupling in the triple transgenic model of Alzheimer's disease: Impaired cerebral blood flow response to neuronal-derived nitric oxide signaling," Experimental Neurology **291**, 36–43 (2017).

65. P. S. Sharp, K. E. Ameen-Ali, L. Boorman, S. Harris, S. Wharton, C. Howarth, O. Shabir, P. Redgrave, and J. Berwick, "Neurovascular coupling preserved in a chronic mouse model of Alzheimer's disease: Methodology is critical," J Cereb Blood Flow Metab **40**, 2289–2303 (2020).

66. O. Shabir, B. Pendry, L. Lee, B. Eyre, P. S. Sharp, M. A. Rebollar, D. Drew, C. Howarth, P. R. Heath, S. B. Wharton, S. E. Francis, and J. Berwick, "Assessment of neurovascular coupling and cortical spreading depression in mixed mouse models of atherosclerosis and Alzheimer's disease," eLife **11**, e68242 (2022).

67. E. Gutiérrez-Jiménez, H. Angleys, P. M. Rasmussen, M. J. West, L. Catalini, N. K. Iversen, M. S. Jensen, S. Frische, and L. Østergaard, "Disturbances in the control of capillary flow in an aged APPswe/PS1ΔE9 model of Alzheimer's disease," Neurobiology of Aging **62**, 82–94 (2018).

68. P. Kelly, P. Denver, S. C. Satchell, M. Ackermann, M. A. Konerding, and C. A. Mitchell, "Microvascular ultrastructural changes precede cognitive impairment in the murine APPswe/PS1dE9 model of Alzheimer's disease," Angiogenesis **20**, 567–580 (2017).

69. K. W. Walek, S. Stefan, J.-H. Lee, P. Puttigampala, A. H. Kim, S. W. Park, P. J. Marchand, F. Lesage, T. Liu, Y.-W. A. Huang, D. A. Boas, C. Moore, and J. Lee, "Near-lifespan longitudinal tracking of brain microvascular morphology, topology, and flow in male mice," Nat Commun **14**, 2982 (2023).

70. Ş. E. Erdener and T. Dalkara, "Small Vessels Are a Big Problem in Neurodegeneration and Neuroprotection," Front Neurol **10**, 889 (2019).

71. G. Brezzo, J. Simpson, K. E. Ameen-Ali, J. Berwick, and C. Martin, "Acute effects of systemic inflammation upon the neuro-glial-vascular unit and cerebrovascular function," Brain, Behavior, & Immunity - Health **5**, 100074 (2020).

72. B. Rosengarten, S. Wolff, S. Klatt, and R. T. Schermuly, "Effects of inducible nitric oxide synthase inhibition or norepinephrine on the neurovascular coupling in an endotoxic rat shock model," Crit Care **13**, R139 (2009).

73. A. B. Lopez-Rodriguez, E. Hennessy, C. L. Murray, A. Nazmi, H. J. Delaney, D. Healy, S. G. Fagan, M. Rooney, E. Stewart, A. Lewis, N. de Barra, P. Scarry, L. Riggs-Miller, D. Boche, M. O. Cunningham, and C. Cunningham, "Acute systemic inflammation exacerbates neuroinflammation in Alzheimer's disease: IL-1β drives amplified responses in primed astrocytes and neuronal network dysfunction," Alzheimer's & Dementia **17**, 1735–1755 (2021).

74. R. Doenlen, U. Krügel, T. Wirth, C. Riether, A. Engler, G. Prager, H. Engler, M. Schedlowski, and G. Pacheco-López, "Electrical activity in rat cortico-limbic structures after single or repeated administration of lipopolysaccharide or staphylococcal enterotoxin B," Proc. R. Soc. B. **278**, 1864–1872 (2011).

75. K. Odoj, B. Brawek, N. Asavapanumas, N. Mojtahedi, M. T. Heneka, and O. Garaschuk, "In vivo mechanisms of cortical network dysfunction induced by systemic inflammation," Brain, Behavior, and Immunity **96**, 113–126 (2021).

76. T. P. Carvalho, F. A. O. Toledo, D. F. A. Bautista, M. F. Silva, J. B. S. Oliveira, P. A. Lima, F. B. Costa, N. Q. Ribeiro, J.-Y. Lee, A. Birbrair, T. A. Paixão, R. M. Tsolis, and R. L. Santos, "Pericytes modulate endothelial inflammatory response during bacterial infection," mBio **15**, e0325223 (2024).

77. C. Cai, C. He, S. Grubb, L. Tao, K. Kılıç, X. Zhang, N. Sheikh, and A. Devor, "Distinct Ca2+ signatures of leptomeningeal fibroblast subgroups in awake mouse brains in health and inflammation," (2025).

78. M. Go, J. Kou, J.-E. Lim, J. Yang, and K. Fukuchi, "Microglial response to LPS increases in wild-type mice during aging but diminishes in an Alzheimer's mouse model: Implication of TLR4 signaling in disease progression," Biochemical and Biophysical Research Communications **479**, 331–337 (2016).

79. J. L. Jankowsky, D. J. Fadale, J. Anderson, G. M. Xu, V. Gonzales, N. A. Jenkins, N. G. Copeland, M. K. Lee, L. H. Younkin, S. L. Wagner, S. G. Younkin, and D. R. Borchelt, "Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase," Human Molecular Genetics **13**, 159–170 (2004).

80. K. Kılıç, M. Desjardins, J. Tang, M. Thunemann, S. Sunil, Ş. E. Erdener, D. D. Postnov, D. A. Boas, and A. Devor, "Chronic Cranial Windows for Long Term Multimodal Neurovascular Imaging in Mice," Front. Physiol. **11**, 612678 (2021).

81. R. L. Lowery and A. K. Majewska, "Intracranial Injection of Adeno-associated Viral Vectors," JoVE 2140 (2010).

82. L. Qin, X. Wu, M. L. Block, Y. Liu, G. R. Breese, J.-S. Hong, D. J. Knapp, and F. T. Crews, "Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration," Glia **55**, 453–462 (2007).

83. A. Y. Shih, J. D. Driscoll, P. J. Drew, N. Nishimura, C. B. Schaffer, and D. Kleinfeld, "Two-Photon Microscopy as a Tool to Study Blood Flow and Neurovascular Coupling in the Rodent Brain," J Cereb Blood Flow Metab **32**, 1277–1309 (2012).

84. E. A. Pnevmatikakis and A. Giovannucci, "NoRMCorre: An online algorithm for piecewise rigid motion correction of calcium imaging data," Journal of Neuroscience Methods **291**, 83–94 (2017).

85. R. Srinivasan, B. S. Huang, S. Venugopal, A. D. Johnston, H. Chai, H. Zeng, P. Golshani, and B. S. Khakh, "Ca2+ signaling in astrocytes from Ip3r2–/– mice in brain slices and during startle responses in vivo," Nat Neurosci **18**, 708–717 (2015).

86. J. L. Stobart, K. D. Ferrari, M. J. P. Barrett, M. J. Stobart, Z. J. Looser, A. S. Saab, and B. Weber, "Long-term In Vivo Calcium Imaging of Astrocytes Reveals Distinct Cellular Compartment Responses to Sensory Stimulation," Cerebral Cortex **28**, 184–198 (2018).

87. J. N. Haidey, G. Peringod, A. Institoris, K. A. Gorzo, W. Nicola, M. Vandal, K. Ito, S. Liu, C. Fielding, F. Visser, M. D. Nguyen, and G. R. Gordon, "Astrocytes regulate ultra-slow arteriole oscillations via stretch-mediated TRPV4-COX-1 feedback," Cell Reports **36**, 109405 (2021).

88. R. L. Rungta, M. Zuend, A.-K. Aydin, É. Martineau, D. Boido, B. Weber, and S. Charpak, "Diversity of neurovascular coupling dynamics along vascular arbors in layer II/III somatosensory cortex," Commun Biol **4**, 855 (2021).

89. M. J. P. Barrett, K. D. Ferrari, J. L. Stobart, M. Holub, and B. Weber, "CHIPS: an Extensible Toolbox for Cellular and Hemodynamic Two-Photon Image Analysis," Neuroinform **16**, 145–147 (2018).

90. P. Y. Chhatbar and P. Kara, "Improved blood velocity measurements with a hybrid image filtering and iterative Radon transform algorithm," Front. Neurosci. **7**, (2013).